Display options
Cite
Park HR, Lee EJ, Moon SC, et al. Inhibition of lung cancer growth by HangAmDan-B is mediated by macrophage activation to M1 subtype. Oncol Lett. 2017;13(4):2330-2336doi: 10.3892/ol.2017.5730.
Park, H. R., Lee, E. J., Moon, S. C., Chung, T. W., Kim, K. J., Yoo, H. S., Cho, C. K., & Ha, K. T. (2017). Inhibition of lung cancer growth by HangAmDan-B is mediated by macrophage activation to M1 subtype. Oncology letters, 13(4), 2330-2336. https://doi.org/10.3892/ol.2017.5730
Park, Hye-Rin, et al. "Inhibition of lung cancer growth by HangAmDan-B is mediated by macrophage activation to M1 subtype." Oncology letters vol. 13,4 (2017): 2330-2336. doi: https://doi.org/10.3892/ol.2017.5730
Park HR, Lee EJ, Moon SC, Chung TW, Kim KJ, Yoo HS, Cho CK, Ha KT. Inhibition of lung cancer growth by HangAmDan-B is mediated by macrophage activation to M1 subtype. Oncol Lett. 2017 Apr;13(4):2330-2336. doi: 10.3892/ol.2017.5730. Epub 2017 Feb 13. PMID: 28454399; PMCID: PMC5403442.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2017 Apr;13(4):2330-2336. doi: 10.3892/ol.2017.5730. Epub 2017 Feb 13.

Inhibition of lung cancer growth by HangAmDan-B is mediated by macrophage activation to M1 subtype.

Oncology letters

Hye-Rin Park, Eun-Ji Lee, Seong-Cheol Moon, Tae-Wook Chung, Keuk-Jun Kim, Hwa-Seung Yoo, Chong-Kwan Cho, Ki-Tae Ha

Affiliations

  1. School of Korean Medicine and Korean Medical Research Center for Healthy Aging, Pusan National University, Yangsan, Gyeongsangnam 50612, Republic of Korea.
  2. Department of Clinical Pathology, TaeKyeung University, Gyeongsan, Gyeongsangbuk 38547, Republic of Korea.
  3. East-West Cancer Center, Dunsan Oriental Medical Hospital of Daejeon University, Daejeon 32100, Republic of Korea.

PMID: 28454399 PMCID: PMC5403442 DOI: 10.3892/ol.2017.5730

Abstract

Re-education of tumor-associated macrophages (TAMs) toward antitumor effectors may be a promising therapeutic strategy for the successful treatment of cancer. HangAmDan-B (HAD-B), a herbal formula, has been used for stimulating immune function and activation of vital energy to cancer patients in traditional Korean Medicine. Previous studies have reported the anti-angiogenic and anti-metastatic effects of HAD-B; however, evidence on the immunomodulatory action of HAD-B was not demonstrated. In the present study, immunocompetent mice were used to demonstrate the suppression of the

Keywords: HangAmDan-B; M1; apoptosis; lung cancer; macrophage

References

  1. Oncol Rep. 2011 Dec;26(6):1601-8 - PubMed
  2. J Clin Invest. 2012 Mar;122(3):787-95 - PubMed
  3. Mol Med Rep. 2015 Sep;12(3):3787-94 - PubMed
  4. Int J Oncol. 2014 Feb;44(2):385-92 - PubMed
  5. Oncotarget. 2015 Apr 30;6(12):10592-603 - PubMed
  6. Cancer Res. 2006 Jan 15;66(2):605-12 - PubMed
  7. Immunity. 2014 Jul 17;41(1):49-61 - PubMed
  8. Sci Rep. 2015 Sep 24;5:14273 - PubMed
  9. Trends Immunol. 2002 Nov;23(11):549-55 - PubMed
  10. J Leukoc Biol. 2009 Nov;86(5):1065-73 - PubMed
  11. BMC Cancer. 2015 Aug 08;15:577 - PubMed
  12. Eur J Cancer. 2006 Apr;42(6):717-27 - PubMed
  13. J Pharmacopuncture. 2012 Sep;15(3):19-30 - PubMed
  14. Sci China Life Sci. 2011 Mar;54(3):248-54 - PubMed
  15. Trends Immunol. 2012 Mar;33(3):119-26 - PubMed
  16. Cancers (Basel). 2014 Aug 13;6(3):1670-90 - PubMed
  17. Front Cell Dev Biol. 2015 May 29;3:33 - PubMed
  18. PLoS One. 2013 Jun 25;8(6):e65896 - PubMed
  19. Trends Immunol. 2015 Apr;36(4):229-39 - PubMed
  20. Nitric Oxide. 2008 Sep;19(2):95-102 - PubMed
  21. Biochim Biophys Acta. 2015 Apr;1855(2):123-30 - PubMed
  22. Hematol Oncol. 2015 Jun;33(2):110-2 - PubMed
  23. BMC Med. 2015 Mar 05;13:45 - PubMed

Publication Types